Vifor Pharma

Vifor Pharma Group is a global specialty pharmaceuticals company and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care; Relypsa; and OM Pharma. Vifor Pharma Group is headquartered in Switzerland.

Vifor Pharma
Traded asSIX: VIFN
ISINCH0364749348 
IndustryPharmaceutical
Founded1933
Headquarters
Switzerland
Areas served
Worldwide
Key people
Jacques Theurillat (Chairperson), Stefan Schulze (CEO) , Colin Bond (CFO)
Websitewww.viforpharma.com

General information

Vifor Pharma is active in the treatment of iron deficiency and iron deficiency anaemia.[1] The Group also has a focus on the management of conditions in nephrology, cardiology and rare diseases.

In 2017, Vifor Pharma Group was listed (ticker symbol VIFN) on the Swiss Stock Exchange (SIX) after splitting up the former Galenica Group. This was completed through an initial public offering (IPO) of Galenica Santé (listed as GALE).

Vifor Pharma Group is a member of a number of trade associations that advocate on behalf of the pharmaceutical industry and for the policy positions commonly shared, this includes the European Federation of Pharmaceutical Industries and Associations (EFPIA).[2]

Structure and operations

Vifor Pharma Group is present in North and South America, Europe, the Middle East and Asia Pacific and works with over 100 partners all around the world.

Vifor Pharma Group develops, manufactures and markets pharmaceutical products including prescription and non-prescription products. The Group’s businesses include:

Vifor Pharma – focused on iron deficiency and iron deficiency anaemia. The product portfolio includes:

  • Ferinject® / Injectafer® (ferric carboxymaltose)
  • Venofer® (iron sucrose)
  • Maltofer® (iron polymaltose)

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) – focused on kidney disease patients, including anaemia, mineral and bone management, cardio-renal conditions, and rare diseases. The product portfolio includes:

  • Mircera® (methoxy polyethylene glycol-epoetin beta), anaemia
  • Velphoro® (polynuclear iron (III)-oxyhydroxide, sucroferric oxyhydroxide), mineral and bone management
  • Rayaldee® (calcifediol), mineral and bone management
  • OsvaRen® (calcium acetate and magnesium carbonate), mineral and bone management
  • Veltassa® (patiromer), cardio-renal conditions, specifically hyperkalaemia

OM Pharma – focused on infectious diseases and the immune system. The product portfolio includes:

  • Broncho-Vaxom® (bacterial lysate medicines), recurrent respiratory tract infections
  • Dicynone® (Etamsylate), menometrorrhagia
  • Doxium® (calcium dobesilate), diabetic retinopathy
  • Uro-Vaxom® (immunoactive Escherichia coli extract), recurrent urinary tract infection

Across the Group there are manufacturing and R&D sites in Switzerland and Portugal. Raw materials are sourced globally with active pharmaceutical ingredients manufactured in Switzerland, Germany and Austria. Final products are manufactured by partners across Europe, Turkey and North America.


History
  • In 1872, Caspar Friedrich Hausmann founds a pharmacy in St. Gallen
  • In 1927, 16 pharmacists establish a joint purchasing centre, Collaboration Pharmaceutique SA, which went on to be renamed Galenica AG in 1933 (later to be renamed Vifor Pharma Ltd. in 2017)
  • In 1944, The pharmacist René Grosclaude founds Vifor Ltd; the company produces over-the-counter medicines
  • In 1983, Hausmann AG laboratories is acquired by Galenica
  • In 1991, Vifor (International) Ltd. is founded and takes over the work of Laboratorien Hausmann in developing new iron products
  • In 2008, Vifor Pharma is founded following the $915 million acquisition of a Canadian company, Aspreva Pharmaceutical Corporation[3], Vifor Ltd. and Vifor (international) Ltd. are integrated in Vifor Pharma.
  • In 2009, Galenica acquires OM Pharma, a Swiss biotechnology company
  • In 2010, Vifor Pharma Group and Fresenius Medical Care found the joint company Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
  • In 2014, Galenica is divided into two divisions, Vifor Pharma and Galenica Santé
  • In 2016, Relypsa, a US based biotechnology company, is purchased for $1.53 billion[4]
  • In 2017, the IPO of Galenica Santé (GALE) is completed and listed on the Swiss Stock Exchange. Galenica AG (GALE) and Vifor Pharma AG (VIFN) are listed as independent entities since
  • In 2019, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) received the Swiss Success Award from the non-profit organisation Swiss Biotech Association[5]
gollark: Also, I have vital* data in the form of my Discord bot's database and website comments, and at least two people would be mildly irritated at the loss of those.
gollark: My journal is stored electronically, and I do somewhat want that, and it would be annoying if I lost my large media libraries.
gollark: I store a bunch of data on a ~10-year-old 7.2krpm HDD and the last backups are from August or so, fun™.
gollark: SSDs are still about 4x the price/GB.
gollark: According to the interweb™ you get 80 to 160MB/s or so from a HDD.

References
  1. https://www.globenewswire.com/news-release/2019/04/26/1810348/0/en/Anemia-Treatment-Drugs-2019-Global-Market-Study-Analyzed-by-Type-of-Anemia-Type-of-Drug-and-Geography.html
  2. https://www.efpia.eu/about-us/membership/
  3. https://www.reuters.com/article/us-galenica-aspreva-idUSL1833840120071018
  4. https://www.reuters.com/article/us-relypsa-m-a-galenica-idUSKCN1010I5
  5. https://www.swissbiotech.org/2019/05/07/medienmitteilung-schweizer-biotechnologie-investitionen-auf-rekordniveau-und-ausgezeichnete-erfolgsgeschichten/
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.